论文部分内容阅读
上海新先锋药业有限公司于6月28日挂牌成立,这标志着上海医药(集团)有限公司实现了整合上海抗生素企业优势的目标,揭开了抗生素工业的新篇章。 上海新先锋药业有限公司是由被誉为“中国抗生素摇篮”的先锋药业、中国民族医药工业的先驱新亚药业和具有百年历史的上海第四制药组成的。上海医药(集团)有限公司、中国长城资产管理公司、中国信达资产管理公司和上海国际信托投资有限公司四大公司分别出资50％、39.1％、8.07％和2.92％,总资产达10亿元人民币。并按照现代企业制度的要求,建立了董事会和监事会。由戴家骅担任董事长,吴建文担任
Shanghai New Pioneer Pharmaceutical Co., Ltd. was established on June 28, marking the goal of Shanghai Pharmaceutical (Group) Co., Ltd. to consolidate the advantages of Shanghai's antibiotic enterprises and opened a new chapter in the antibiotic industry. Shanghai New Pioneer Pharmaceutical Co., Ltd. is composed of Pioneer Pharmaceuticals, known as “Cradle of Chinese Antibiotic Drugs”, New Asia Pharmaceutical Co., a pioneer of China's national pharmaceutical industry and Shanghai No.4 Pharmaceutical Co., Ltd., which has a history of more than 100 years. Shanghai Pharmaceutical (Group) Co., Ltd., China Great Wall Asset Management Corporation, China Cinda Asset Management Corporation and Shanghai International Trust and Investment Co., Ltd. invested 40%, 39.1%, 8.07% and 2.92% respectively in the four major companies with total assets of RMB1 billion RMB. In accordance with the requirements of the modern enterprise system, the Board of Directors and the Board of Supervisors have been established. By Dai Jiahua as chairman, Wu Jianwen served